Abstract library

814 results for "PNET stage IV surgery ki67".
#1852 Is Ki67 Index in Biopsy Tissue Truly Reflect Grading of Pancreatic Neuroendocrine Neoplasm?
Introduction: Ki67 index is essential for progression and treatment of pancreatic neuroendocrine neoplasm (pNEN). For advanced pNEN patient(pts), Ki67 scoring by core/fine-needle biopsy is used to evaluate pNEN pts’ grade.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Heli Gao
Authors:
Keywords: pNEN, Ki67, biopsy, surgery
#1376 Pancreatic Neuroendocrine Tumors: Experience of a Tertiary Care Center
Introduction: Pancreatic neuroendocrine tumors (PNET) are rare functionally and biologically heterogeneous tumors accounting for less than 5% of pancreatic cancer
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Rita Assi
Authors:
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola
Authors:
#485 Laparoscopic Surgery of Pancreatic Neuroendocrine Tumors: Results From a Tertiary Care Institution
Introduction: There are only a few series describing feasibility and short-term-outcome of laparoscopic surgery of pancreatic neuroendocrine tumors (pNET).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Sven-Petter Haugvik
Authors:
#2204 Pancreatic Neuroendocrine Tumors: Analysis of Prognostic Factors After Surgical Resection in a Single Centre
Introduction: Pancreatic neuroendocrine tumors (PNET) are rare, heterogeneous and challenging neoplasms. Surgical resection is the only curative treatment. Recurrence can occur even after years. Diagnosis of malignancy is difficult so further studies are necessary to identify prognostic criteria.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Laia Blanco Cuso
Authors:
Keywords: PNETS, Prognosis
#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Drs. Anela Blazevic
Authors:
#779 Results of Pancreatic Surgery for Neuroendocrine Tumors: Single Center Experience with No Perioperative Mortality
Introduction: Pancreatic neuroendocrine tumors (p-NET).
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: Dr Roberto Valente
Authors:
Keywords: p-NET, surgery
#1604 Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas: A Nordic Multicenter Study
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Currently, resection of liver metastases in patients with metastatic GEP-NEC is not recommended. However, the existing data are scarce.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: MD Renate Berget Galleberg
Authors:
#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs
Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Professor Mark Kidd
Authors:
#581 Loss of Succinate Dehydrogenase (SDHB) Expression in Midgut Carcinoids as Prognostic Factor: a New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?
Introduction: Gene mutations of SDH complex have been involved in the pathogenesis of cancer cells. These mutations are often associated with loss of activity of SDH subunity B and overexpression of HIF-1a, which play a central role in angiogenesis.
Conference:
Category: Basic
Presenting Author: Dr. Massimo Milione
Authors: